Beierda Pharmaceuticals

Beijing Beierda Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Beijing, China, focused on the development of innovative small molecule targeted therapies for oncology. The company was founded by Dr. Zhang Xiaofeng, a prominent scientist and co-founder of Betta Pharmaceuticals, and maintains a strategic focus on addressing resistance mechanisms in cancer treatment. Its lead product candidate, BPI-7711 (Limertinib), is a third-generation EGFR tyrosine kinase inhibitor (TKI) targeting the T790M mutation in non-small cell lung cancer (NSCLC). Beyond its lead program, Beierda is advancing a pipeline of novel agents including TLR7 agonists and BET inhibitors to treat various solid tumors and hematological malignancies. The company leverages its deep expertise in medicinal chemistry to develop high-selectivity compounds with improved safety profiles. Beierda continues to progress its clinical programs toward commercialization in the Chinese market.